Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A

rFVIIIFc (efraloctocog alfa, Eloctate(®)) is an extended half-life (EHL) factor VIII licensed for use in patients with hemophilia A for prophylaxis and treatment of bleeding and surgical episodes. Pharmacokinetic studies in adults have shown a mean 1.5-fold increase in half-life compared to full-len...

Descripción completa

Detalles Bibliográficos
Autores principales: Chowdary, Pratima, Fosbury, Emma, Riddell, Anne, Mathias, Mary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028163/
https://www.ncbi.nlm.nih.gov/pubmed/27695377
http://dx.doi.org/10.2147/JBM.S80814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028163/
https://www.ncbi.nlm.nih.gov/pubmed/27695377
http://dx.doi.org/10.2147/JBM.S80814

Ejemplares similares